At the European Lung Cancer Congress (ELCC) in 2022, Hu Jian's research proved for the first time that almonertinib had significant efficacy and good safety as postoperative adjuvant treatment of stage I-III NSCLC with EGFR mutation [13]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.